X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs SUVEN LIFE - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA SUVEN LIFE ELDER PHARMA/
SUVEN LIFE
 
P/E (TTM) x -0.2 14.1 - View Chart
P/BV x 0.1 3.4 3.0% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 ELDER PHARMA   SUVEN LIFE
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
SUVEN LIFE
Mar-17
ELDER PHARMA/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs380229 166.3%   
Low Rs188151 124.4%   
Sales per share (Unadj.) Rs491.242.7 1,150.2%  
Earnings per share (Unadj.) Rs-3.26.9 -46.4%  
Cash flow per share (Unadj.) Rs14.48.5 168.9%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs376.552.4 718.5%  
Shares outstanding (eoy) m20.54127.28 16.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.64.4 13.0%   
Avg P/E ratio x-89.327.7 -322.2%  
P/CF ratio (eoy) x19.722.2 88.6%  
Price / Book Value ratio x0.83.6 20.8%  
Dividend payout %014.6 0.0%   
Avg Mkt Cap Rs m5,83324,158 24.1%   
No. of employees `000NA1.0 0.0%   
Total wages/salary Rs m2,179522 417.7%   
Avg. sales/employee Rs ThNM5,349.7-  
Avg. wages/employee Rs ThNM513.5-  
Avg. net profit/employee Rs ThNM858.1-  
INCOME DATA
Net Sales Rs m10,0895,435 185.6%  
Other income Rs m257211 121.7%   
Total revenues Rs m10,3465,646 183.2%   
Gross profit Rs m-7921,291 -61.4%  
Depreciation Rs m361214 168.8%   
Interest Rs m2,75657 4,852.6%   
Profit before tax Rs m-3,6531,231 -296.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125359 34.9%   
Profit after tax Rs m-65872 -7.5%  
Gross profit margin %-7.823.7 -33.1%  
Effective tax rate %-3.429.2 -11.8%   
Net profit margin %-0.616.0 -4.0%  
BALANCE SHEET DATA
Current assets Rs m9,2404,917 187.9%   
Current liabilities Rs m9,9981,186 842.9%   
Net working cap to sales %-7.568.6 -10.9%  
Current ratio x0.94.1 22.3%  
Inventory Days Days4662 74.5%  
Debtors Days Days6031 194.8%  
Net fixed assets Rs m10,1243,154 320.9%   
Share capital Rs m206127 161.6%   
"Free" reserves Rs m5,5826,543 85.3%   
Net worth Rs m7,7346,670 115.9%   
Long term debt Rs m4,889259 1,885.5%   
Total assets Rs m22,8828,157 280.5%  
Interest coverage x-0.322.7 -1.4%   
Debt to equity ratio x0.60 1,626.2%  
Sales to assets ratio x0.40.7 66.2%   
Return on assets %11.811.4 103.3%  
Return on equity %-0.813.1 -6.5%  
Return on capital %22.318.6 120.1%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m3074,996 6.1%   
Fx outflow Rs m125959 13.1%   
Net fx Rs m1814,037 4.5%   
CASH FLOW
From Operations Rs m11,7541,088 1,080.0%  
From Investments Rs m-561-3,107 18.0%  
From Financial Activity Rs m-6,762-300 2,252.4%  
Net Cashflow Rs m4,432-2,319 -191.1%  

Share Holding

Indian Promoters % 39.6 63.4 62.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 0.0 -  
FIIs % 16.8 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 36.5 98.9%  
Shareholders   16,479 37,287 44.2%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   DR. REDDYS LAB  IPCA LABS  ASTRAZENECA PHARMA  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare ELDER PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red; SBI Up 3.7%(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS